Enlivex terminates RAIN token financing deal with Rain Foundation
The company ended a July 2026 stock purchase agreement that would have paid it in RAIN tokens, canceling plans for a shareholder vote.
Enlivex Ltd. announced on September 22, 2026 that it had terminated a securities purchase agreement with the Rain Foundation, under which the company had planned, pending shareholder approval, to sell and issue to the Rain Foundation in a private placement 66,666,667 of the company's ordinary shares, with the investor electing to pay in RAIN tokens.1
The agreement was originally entered into on July 27, 2026, according to the company's 6-K filing. Enlivex ended the agreement using its own termination rights, meaning the private placement will not go forward and the company will no longer seek shareholder approval for it.1 Terms of the original deal were detailed in a separate 6-K filed with the SEC on July 28, 2026, which the company incorporated by reference in this latest filing.
Enlivex described itself in the release as a quality longevity company powered by a prediction markets treasury.1 The company said it is developing Allocetra, which it called an immunotherapy in clinical development aimed at inflammation tied to aging, with osteoarthritis related to age as its main target. It also said it runs a prediction markets treasury strategy built around the Rain protocol, described by the company as the leading decentralized prediction markets infrastructure on Arbitrum.1
The press release was filed as Exhibit 99.1 to the Form 6-K, signed by CEO Oren Hershkovitz on September 22, 2026.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.